Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plant-based diets, health and fitness programmes for those interested in veganism to improve their health and wellbeing. Skinny Bitch's book has sold more than 1.1m copies and is available in 6 languages. Readers of the book include celebrities such as Eva Longoria and Jessica Alba. Ellen DeGeneres has stated that the Skinny Bitch book is the reason she became vegan.
The company is now expanding their brand further by offering their content through online guides and blogs. Skinny Bitch is also intending to generate revenue via vegan supplements produced in the US to be sold through their website and third party e-commerce channels.
days to go:
Expired
investment:
£75,810
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
Peliwica Insurance is set up to disrupt the current rural, equine, and agriculture insurance broker markets. It is a new Insuretech business that was launched in 2018. In the same year, the company gained its first FCA Approval and the Lloyds CoverHolder status that held the key enablers to launch this business. Peliwica Insurance is trading with 10 Brokers with a £100m premium opportunity. With its upcoming mobile application and devised white-labelled D2C platforms, the company will be able to allow brokers to access new product markets and customers more effectively.
days to go:
Expired
investment:
£75,980
Personalised Protein Co (PPCo) is a direct-to-consumer supplement brand that bridges the gap between technology and fitness. Leveraging on the growing UK vitamin and supplement industry, which is worth over £800m, PPCo offers expert guidance, bespoke product, clear pricing, and consumer-friendly subscription service. More than 9,000 people have signed up for the company's pre-registered launch campaign providing it 1,200 customers and 5000+ Instagram followers. With the proceeds, the company will improve its technology, automation, and aim at acquiring new customers. PPCo is raising money to invest in its product and scale its marketing efforts.
days to go:
Expired
investment:
£192,770
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.
days to go:
Expired
investment:
£142,840
Charm is a peer-to-peer impact investment platform that allows a user to use his/her investments to drive positive change in the world while earning a financial return. Morgan Stanley estimates that 85% of people are interested in sustainable investing. Charm enables individuals to fund projects led by high-impact entrepreneurs selling clean energy solutions in developing economies. Users can view their investments on the company's transparent, personalised impact investment dashboard, as well as, earn social, environmental and financial bottom line returns for their contributions. The company secured a £496,000 grant funding to develop its platform, refine its offering & provide growth capital. It is in the process of becoming an appointed representative of a Financial Conduct Authority (FCA) authorised entity post this funding round. It will use the investment to expand its team, develop its platform, and raise brand awareness.
days to go:
Expired
investment:
£273,720
